Clinical NGS Data Analysis Market Projected to Reach $9.4 Billion by 2030 Amidst Personalized Medicine Demand
The clinical Next-Generation Sequencing (NGS) data analysis market is experiencing significant growth, with projections indicating a rise from $4.98 billion in 2026 to $9.4 billion by 2030, at a compound annual growth rate (CAGR) of 17.2%. This expansion is driven by several factors, including the increasing adoption of NGS in clinical diagnostics, advancements in precision medicine programs, and a surge in genomic research. The market's growth is also fueled by decreasing sequencing costs and improved access to bioinformatics tools. Key trends shaping this future include the integration of artificial intelligence (AI) in genomic interpretation, a growing demand for personalized medicine, and the expansion of clinical genomics, particularly in oncology and rare diseases. Furthermore, the wider uptake of cloud-based healthcare platforms and a heightened regulatory focus on genomic data governance are contributing to this upward trajectory. The Business Research Company highlights that North America held the...